|
1
|
Stewart BW and Wild CP: World Cancer
Report 2014. IARC Press; Lyon: 2014
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marventano S, Forjaz M, Grosso G,
Mistretta A, Giorgianni G, Platania A, Gangi S, Basile F and Biondi
A: Health related quality of life in colorectal cancer patients:
State of the art. BMC Surg. 13 (Suppl 2):S152013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Helsingen LM, Vandvik PO, Jodal HC,
Agoritsas T, Lytvyn L, Anderson JC, Auer R, Murphy SB, Almadi MA,
Corley DA, et al: Colorectal cancer screening with faecal
immunochemical testing, sigmoidoscopy or colonoscopy: A clinical
practice guideline. BMJ. 367:l55152019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weiss JB, Cetel NS and Weiss DE: To the
Editor: Colorectal cancer screening: Colonoscopy has disadvantages.
Cleve Clin J Med. 86:774–776. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wong CK, Fedorak RN, Prosser CI, Stewart
ME, van Zanten SV and Sadowski DC: The sensitivity and specificity
of guaiac and immunochemical fecal occult blood tests for the
detection of advanced colonic adenomas and cancer. Int J Colorectal
Dis. 27:1657–1664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van Rossum LG, van Rijn AF, Verbeek AL,
van Oijen MG, Laheij RJ, Fockens P, Jansen JB, Adang EM and Dekker
E: Colorectal cancer screening comparing no screening,
immunochemical and guaiac fecal occult blood tests: A
cost-effectiveness analysis. Int J Cancer. 128:1908–1917. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan S, Han B, Gao S, Wang X, Wang Z, Wang
F, Zhang J, Xu D and Sun B: Exosome-Encapsulated microRNAs as
circulating biomarkers for colorectal cancer. Oncotarget.
8:60149–60158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai J, Zuo X, Chen Z, Zhang Y, Wang J,
Wang J, Ye X and Zhao W: Long noncoding RNAs serve as potential
diagnostic biomarkers for colorectal cancer. J Cancer. 10:611–619.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Zhu M, Shan X, Zhou X, Wang T,
Zhang J, Tao J, Cheng W, Chen G, Li J, et al: A panel of
seven-miRNA signature in plasma as potential biomarker for
colorectal cancer diagnosis. Gene. 687:246–254. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu H: Reference intervals for
gastrointestinal tumor markers (AFP, CEA, CA199 and CA724) in
healthy adults of han nationality in chongqing by roche ECLIA
system. Scand J Clin Lab Invest. 79:484–490. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong D, Zhang L, Jia L, Ji W, Wang Z, Ren
L, Niu R and Zhou Y: Identification of serum periostin as a
potential diagnostic and prognostic marker for colorectal cancer.
Clin Lab. 64:973–981. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song S, Hong JC, McDonnell SE, Koong AC,
Minsky BD, Chang DT and Liauw SL: Combined modality therapy for
rectal cancer: The relative value of posttreatment versus
pretreatment CEA as a prognostic marker for disease recurrence. Ann
Surg Oncol. 19:2471–2476. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tarantino I, Warschkow R, Schmied BM,
Güller U, Mieth M, Cerny T, Büchler MW and Ulrich A: Predictive
value of CEA for survival in stage I rectal cancer: A
population-based propensity score-matched analysis. J Gastrointest
Surg. 20:1213–1222. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Holdenrieder S, Dharuman Y, Standop J,
Trimpop N, Herzog M, Hettwer K, Simon K, Uhlig S and Micallef J:
Novel serum nucleosomics biomarkers for the detection of colorectal
cancer. Anticancer Res. 34:2357–2362. 2014.PubMed/NCBI
|
|
17
|
Webb A, Scott-Mackie P, Cunningham D,
Norman A, Andreyev J, O'Brien M and Bensted J: The prognostic value
of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG
immunohistochemistry in advanced colorectal cancer. Ann Oncol.
6:581–587. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Wang X, Yu F, Chen J, Zhao S,
Zhang D, Yu Y, Liu X, Tang H and Peng Z: Combined detection of
preoperative serum CEA, CA19-9 and CA242 improve prognostic
prediction of surgically treated colorectal cancer patients. Int J
Clin Exp Pathol. 8:14853–14863. 2015.PubMed/NCBI
|
|
19
|
Isgrò MA, Bottoni P and Scatena R:
Neuron-Specific enolase as a biomarker: Biochemical and clinical
aspects. Adv Exp Med Biol. 867:125–143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barone FC, Clark RK, Price WJ, White RF,
Feuerstein GZ, Storer BL and Ohlstein EH: Neuron-specific enolase
increases in cerebral and systemic circulation following focal
ischemia. Brain Res. 623:77–82. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Muller E, Shock JP, Bender A, Kleeberger
J, Högen T, Rosenfelder M, Bah B and Lopez-Rolon A: Outcome
prediction with serial neuron-specific enolase and machine learning
in anoxic-ischaemic disorders of consciousness. Comput Biol Med.
107:145–152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schmechel D, Marangos PJ and Brightman M:
Neurone-Specific enolase is a molecular marker for peripheral and
central neuroendocrine cells. Nature. 276:834–836. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu L, Lina W and Xuejun Y: The diagnostic
value of serum CEA, NSE and MMP-9 for on-small cell lung cancer.
Open Med (Wars). 11:59–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The Eighth Edition AJCC Cancer Staging Manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qi W, Li X and Kang J: Advances in the
study of serum tumor markers of lung cancer. J Cancer Res Ther.
10:C95–C101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Xu HX, Wang WQ, Wu CT, Xiang JF,
Liu C, Long J, Xu J, Fu de L, Ni QX, et al: Serum CA125 is a novel
predictive marker for pancreatic cancer metastasis and correlates
with the metastasis-associated burden. Oncotarget. 7:5943–5956.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McKeown E, Nelson DW, Johnson EK, Maykel
JA, Stojadinovic A, Nissan A, Avital I, Brücher BL and Steele SR:
Current approaches and challenges for monitoring treatment response
in colon and rectal cancer. J Cancer. 5:31–43. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Campos-da-Paz M, Dórea JG, Galdino AS,
Lacava ZGM and de Fatima Menezes Almeida Santos M: Carcinoembryonic
Antigen (CEA) and hepatic metastasis in colorectal cancer: Update
on biomarker for clinical and biotechnological approache. Recent
Pat Biotechnol. 12:269–279. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sung HJ and Cho JY: Biomarkers for the
lung cancer diagnosis and their advances in proteomics. BMB Rep.
30:615–625. 2008. View Article : Google Scholar
|
|
30
|
Gao Y, Wang J, Zhou Y, Sheng S, Qian SY
and Huo X: Evaluation of serum CEA, CA19-9, CA72-4, CA125 and
ferritin as diagnostic markers and factors of clinical parameters
for colorectal cancer. Sci Rep. 8:27322018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang P, Piao Y, Zhang X, Li W and Hao X:
The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal
fluid can be useful indicators for diagnosis of meningeal
carcinomatosis of lung cancer. Cancer Biomark. 13:123–130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang JL, Wu DW, Cheng ZZ, Han WZ, Xu SW
and Sun NN: Expression of high mobility group box-B1 (HMGB-1) and
matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer
(NSCLC). Asian Pac J Cancer Prev. 15:4865–4869. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaiser E, Kuzmits R, Pregant P, Burghuber
O and Worofka W: Clinical biochemistry of neuron specific enolase.
Clin Chim Acta. 183:13–31. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang WY, Shi G, Wu LP, Wei ST, Huang YN,
Tan LX, Yang RZ, Yan CX, Guo ET, Wang HY, et al: Analysis of
specific serum markers of colon carcinoma using a
bhattacharyya-based support vector machine. Genet Mol Res.
23:162017.
|
|
35
|
Ning S, Wei W, Li J, Hou B, Zhong J, Xie
Y, Liu H, Mo X, Chen J and Zhang L: Clinical significance and
diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels
in gastric and colorectal cancer patients. J Cancer. 9:494–501.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Haque A, Ray SK, Cox A and Banik NL:
Neuron specific enolase: A promising therapeutic target in acute
spinal cord injury. Metab Brain Dis. 31:487–495. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fakih MG and Padmanabhan A: CEA monitoring
in colorectal cancer. What you should know. Oncology (Williston
Park). 20:579–587. 2006.PubMed/NCBI
|
|
38
|
Baqar AR, Wilkins S, Staples M, Angus Lee
CH, Oliva K and McMurrick P: The role of preoperative CEA in the
management of colorectal cancer: A cohort study from two cancer
centres. Int J Surg. 64:10–15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takagawa R, Fujii S, Ohta M, Nagano Y,
Kunisaki C, Yamagishi S, Osada S, Ichikawa Y and Shimada H:
Preoperative serum carcinoembryonic antigen level as a predictive
factor of recurrence after curative resection of colorectal cancer.
Ann Surg Oncol. 15:3433–3439. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS,
Yen CC, Lin TC, Jiang JK, Yang SH, Wang HS and Chen PM:
Preoperative carcinoembryonic antigen level as an independent
prognostic factor in colorectal cancer: Taiwan experience. Jpn J
Clin Oncol. 30:12–16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wiratkapun S, Kraemer M, Seow-Choen F, Ho
YH and Eu KW: High preoperative serum carcinoembryonic antigen
predicts metastatic recurrence in potentially curative colonic
cancer: Results of a five-year study. Dis Colon Rectum. 44:231–235.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang XQ, Chen C, Hou JX, Peng CW, Huang CQ
and Li Y: Preoperative serum carbohydrate antigen 242 is a useful
predictive and prognostic marker in colorectal cancer.
Hepatogastroenterology. 58:377–382. 2011.PubMed/NCBI
|
|
43
|
Okamura R, Hasegawa S, Hida K, Hoshino N,
Kawada K, Sugihara K and Sakai Y; Japanese Study Group for
Postoperative Follow-up of Colorectal Cancer, : The role of
periodic serum CA19-9 test in surveillance after colorectal cancer
surgery. Int J Clin Oncol. 22:96–101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li H, Zhang B, Hu X, Dong Y, Fan Q, Guo F,
Ren X, Zhou H, Tian W and Zhao Y: Serum helicobacter pylori FliD
antibody and the risk of gastric cancer. Oncotarget. 7:22397–22408.
2016. View Article : Google Scholar : PubMed/NCBI
|
